Trimel Pharmaceuticals Corp  

(Public, CVE:JV.P)   Watch this stock  
Find more results for Gregory P. Hawkins´┐Ż
Delayed:   2:14PM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.01 - 0.21
Open     -
Vol / Avg. 0.00/19,467.00
Mkt cap 1.20M
P/E     -
Div/yield     -
EPS -0.10
Shares     -
Beta     -
Inst. own     -
Aug 6, 2015
Q2 2015 Trimel Pharmaceuticals Corp Earnings Call - 8:30AM EDT - Add to calendar
Aug 5, 2015
Q2 2015 Trimel Pharmaceuticals Corp Earnings Release - 9:30AM EDT - Add to calendar
May 7, 2015
Q1 2015 Trimel Pharmaceuticals Corp Earnings Call
May 6, 2015
Q1 2015 Trimel Pharmaceuticals Corp Earnings Release

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1.18% -525.04%
Operating margin -37.66% -502.34%
EBITD margin - -407.84%
Return on average assets -0.21% -43.52%
Return on average equity -1.11% -150.79%
Employees 19 -
CDP Score - -


2488 Dunwin Dr
+1-416-6790771 (Phone)

Website links


Trimel Pharmaceuticals Corporation is a Canada-based development-stage specialty pharmaceutical company. It is engaged in developing medications for male hypogonadism, female sexual dysfunction and respiratory disorders. It holds the development and marketing rights to a bioadhesive intranasal gel drug delivery technology platform and a dry power inhaler, TriVair. Its products include Natesto, Tefina, Estrace and CompleoTRT. Natesto is a testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Tefina is an intranasal, low-dose gel formulation of testosterone, which is being developed as a use as required treatment option for women experiencing Female Orgasmic Disorder. Estrace containing 17 Beta-estradiol, is indicated for symptomatic relief of menopausal symptoms and prevention of osteoporosis. The Company is also developing CompleoTRT for the treatment of male hypogonadism.

Officers and directors

Ian O. Ihnatowycz Independent Chairman of the Board
Age: 61
Tom Rossi President, Chief Executive Officer, Director
Kenneth G. Howling Chief Financial Officer
Matthew Hawkins Vice President - Legal Affairs, Corporate Secretary
Nathan Bryson Vice President - Scientific Affairs
Rolf K. Reininghaus Executive Director, Director
Stephen Robert Gregory Lead Independent Director
Norma Beauchamp Director
Matthew J. Pfeffer CPA Independent Director
Age: 57
Jeffrey D. Sherman Independent Director